Markets

Merit Medical (MMSI) Tops Q3 Earnings & Revenue Estimates

Merit Medical Systems, Inc. MMSI recently reported third-quarter 2018 adjusted earnings per share (EPS) of 47 cents, beating the Zacks Consensus Estimate of 42 cents. EPS improved 46.9% from the year-ago quarter's tally.

The Utah-based provider of peripheral and cardiac intervention products reported worldwide revenues of $221.6 million, up 23.6% from the year-ago quarter's tally. Revenues surpassed the Zacks Consensus Estimate of $218 million.

The stock carries a Zacks Rank #4 (Sell).

Segmental Analysis

The company reports revenues through two segments - the Cardiovascular unit and the Endoscopy division.

The Cardiovascular unit recorded revenues of $212.2 million, up 22.8% year over year. The upside can be attributed to a 32.3% year-over-year increase in the segment's stand-alone devices to $91 million. Moreover, revenues from catheters increased 27.8% to $40.6 million. Inflation devices increased 14.3% year over year to $22.9 million.

Revenues in the Endoscopy division totaled $9.51 million, up 43.8% year over year.

Margins

In the quarter under review, gross profit totaled $102.1 million, up 26.7% on a year-over-year basis. Gross margin came in at 46% of net revenues, up 110 basis points (bps). Per management, the improvement was backed by higher production variances and better product mix.

The company registered selling, general and administrative expenses of $66.4 million, up 21.3% year over year.

The company registered research and development expenses of $14.5 million, up 13.1% year over year.

Net operating income in the quarter totaled $21.1 million.

Merit Medical Systems, Inc. Price and Consensus

Merit Medical Systems, Inc. Price and Consensus | Merit Medical Systems, Inc. Quote

Guidance Raised

Merit Medical reiterated2018 guidance.

The company expects 2018 revenues in the band of $870-$880 million. The Zacks Consensus Estimate for revenues is pegged at $874 million, within the guided range.

Adjusted EPS are expected between $1.60 and $1.70. The Zacks Consensus Estimate for the same is pinned at $1.64, within the projected range.

The company expects adjusted gross margins within 48.9-49.4%.

In Conclusion

Merit Medical exited the third quarter on a solid note, with earnings and revenues beating the consensus mark.

Solid growth in the Cardiovascular segment is a positive along with expansion in gross margin. Solid international growth buoys optimism. Management is optimistic about the alliance with NinePoint Medical, which is already contributing to growth. The recent acquisition of product distribution agreements for the DirectACCESS Medical PTA Balloon Catheter is encouraging as well. The company also became the exclusive worldwide distributor for the Q50 PLUS Stent Graft Balloon. An upbeat guidance for 2018 paints a bright picture as well.

Recently, the company received FDA 510(k) clearance for a series of new tracheal/bronchial mini-stents. The company also received 510(k) clearance for EmboCube product line.

However, surging operating expenses areconcerns. Headwinds like stiff competition and higher consolidation in the healthcare industry add to the woes.

Upcoming Releases From the MedTech Industry

A few better-ranked stocks in the MedTech space are Inogen, Inc INGN , Baxter International Inc BAX and Henry Schein, Inc HSIC .

Inogen is expected to release third-quarter fiscal 2018 results on Nov 6. The Zacks Consensus Estimate is pegged at 52 cents for the quarter's adjusted EPS and the same for revenues is pegged at $91.1. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

Baxter is expected to release third-quarter 2018 results on Oct 31. The Zacks Consensus Estimate for the period's adjusted EPS is 74 cents and the same for revenues is pegged at $2.79 billion. The stock carries a Zacks Rank #2.

Henry Schein is slated to release third-quarter 2018 results on Nov 6. The Zacks Consensus Estimate for adjusted EPS is $1.01for the to-be-reported quarter and the same for the top line is pegged at$3.36 billion. The stock carries a Zacks Rank #2.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Inogen, Inc (INGN): Free Stock Analysis Report

Baxter International Inc. (BAX): Free Stock Analysis Report

Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report

Henry Schein, Inc. (HSIC): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

HSIC BAX MMSI INGN

Other Topics

Earnings Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More